Acceleron Pharma Company Profile (NASDAQ:XLRN)

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Acceleron Pharma Inc. (NASDAQ:XLRN) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.08. The company earned $3.71 million during the quarter, compared to analyst estimates of $3.38 million. Acceleron Pharma had a negative net margin of 659.04% and a negative return on equity of 38.57%. The company's revenue was down 79.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.13 EPS. View Acceleron Pharma's Earnings History.

14 equities research analysts have issued 1 year target prices for Acceleron Pharma's shares. Their predictions range from $20.00 to $63.00. On average, they anticipate Acceleron Pharma's share price to reach $42.75 in the next year. View Analyst Ratings for Acceleron Pharma.

Here are some recent quotes from research analysts about Acceleron Pharma stock:

• 1. Cann analysts commented, "Acceleron Pharma announced today that updated preliminary results from phase II studies of Luspatercept in beta-thalassemia were released at the 22nd Congress of the European Hematology Association. It was reported that results from this ongoing study demonstrate increases in hemoglobin and decreases in red blood cell transfusion burden sustained for up to 24 months, with patients still active on treatment. These data presented today are very encouraging and appear to be as good as or better than data previously presented for Luspatercept." (6/23/2017)
• 2. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (5/11/2017)
• 3. Instinet analysts commented, "We are initiating coverage of Acceleron (XLRN) with a Buy rating and $58 target price. We recommend owning XLRN shares ahead of what we view as underappreciated 2H17 readouts. We foresee upside to the shares following positive results in 2H17 from a Phase 2 study of ACE-083, a myostatin+ inhibitor in FSHD. ACE-083 is a wholly owned program that is not currently ascribed value in XLRN's share price but worth $19/sh, by our estimate. We believe that these near-term data have been obscured by investors' focus on pivotal 2H18 Phase 3 results from Celgene-partnered (20-25% royalties) blockbuster luspatercept in MDS and beta-thalassemia. We expect further share price appreciation from this program in 2H17, as Phase 2 extension data for luspatercept better frames the magnitude of, and potential upside to, the market opportunity from indication expansion in myeloid diseases outside beta-thalassemia and MDS." (3/1/2017)
• 4. Credit Suisse Group analysts commented, "We view Mr Dable’s prior role as President of US Pharmaceuticals Bayer and experience in commercial product launches as a strong strategic fit for XLRN’s future commercialization. Further, Mr Dable brings significant collaboration experience from Bayer deals with Genzyme and Regeneron, where he spearheaded ophthalmology business planning and execution. Our conversation with mgmt. indicates Dr. Knopf will stay involved with XLRN in a scientific capacity, after co-founding the company 13 years ago. Mgmt change prepares XLRN for luspatercept co-commercialization: With ph3 trials in MDS and beta-thalassemia ongoing, we see Mr. Dable bringing significant commercial experience to XLRN. We conservatively model luspatercept sales in ESA-resistant and ring sideroblast-positive (RS+) MDS patients (ph3 MEDALIST population) and transfusion dependent beta- thalassemia patients (ph3 BELIEVE population). We model PoS-unadjusted peak year sales ests. of $908M globally in MDS and $1.1B in beta- thalassemia." (9/28/2016)

Some companies that are related to Acceleron Pharma include GW Pharmaceuticals PLC (GWPH), Axovant Sciences (AXON), Prothena Corporation PLC (PRTA), AveXis (AVXS), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO), Radius Health (RDUS), Aerie Pharmaceuticals (AERI), Spark Therapeutics (ONCE), Sarepta Therapeutics (SRPT), Lexicon Pharmaceuticals (LXRX), Array BioPharma (ARRY), NovoCure Limited (NVCR), BeiGene (BGNE), Omeros Corporation (OMER), Insmed (INSM), Synergy Pharmaceuticals (SGYP) and Xencor (XNCR).

Acceleron Pharma's management team includes the folowing people:

• Francois E. Nader M.D., Independent Chairman of the Board
• Habib J. Dable, President, Chief Executive Officer, Director
• Kevin F. McLaughlin, Chief Financial Officer, Senior Vice President, Treasurer
• Matthew L. Sherman M.D., Executive Vice President and Chief Medical Officer
• Ravindra Kumar Ph.D, Senior Vice President, Chief Scientific Officer
• John D. Quisel J.D., Ph.D., Senior Vice President, Business Development, General Counsel and Secretary
• Jean M. George, Independent Director
• George S. Golumbeski Ph.D., Independent Director
• Terrence C. Kearney, Independent Director
• Tom Maniatis Ph.D., Independent Director

Acceleron Pharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (12.60%), BlackRock Inc. (9.57%), Vanguard Group Inc. (4.98%), Eagle Asset Management Inc. (3.07%), Westfield Capital Management Co. LP (2.99%) and State Street Corp (2.68%). Company insiders that own Acceleron Pharma stock include Corp /De/ Celgene, Jean George, John D Quisel, John L Knopf, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire. View Institutional Ownership Trends for Acceleron Pharma.

Acceleron Pharma's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Granahan Investment Management Inc. MA, FMR LLC, Westfield Capital Management Co. LP, Morgan Stanley, HarbourVest Partners LLC, Jasper Ridge Partners L.P. and Century Capital Management LLC. Company insiders that have sold Acceleron Pharma stock in the last year include Jean George, John D Quisel, John L Knopf, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire. View Insider Buying and Selling for Acceleron Pharma.

Acceleron Pharma's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Eventide Asset Management LLC, Point72 Asset Management L.P., Vanguard Group Inc., VHCP Management II LLC, Pictet Asset Management Ltd., State Street Corp and MARSHALL WACE ASIA Ltd. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

Shares of Acceleron Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Acceleron Pharma stock can currently be purchased for approximately $34.10.